Contact Us

Company News

Home
Blog Standard
Company News
Page 3
Company News September 8, 2022 Oxford Vacmedix Comments: 0

OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder of OVM said: We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the...
Read More
Company News July 27, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test

New patent for a novel diagnostic test to detect anti-microbial resistance filed, after successful completion of development and initial testing Oxford, 27th July 2022 Press Release – Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test Oxford Vacmedix (OVM), the UK clinical stage biopharma company, focused on the development of a new generation of cancer vaccines, announced today that project work to develop a novel diagnostic test for anti-microbia...
Read More
Company News May 25, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays

Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays.  Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix UK Limited (OVM) announced today the award of a Small Business Research Initiative contract from Innovate UK to fu...
Read More
Company News May 23, 2022 Oxford Vacmedix Comments: 0

Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place

Dr Shisong Jiang recieved an invitation to the annual Royal Garden Party to recognise many years’ service to charity. Oxford, 23rd May 2022 Press Release – Dr Shisong Jiang invited to Buckingham Palace On Wednesday 18 May, the Dr Shisong Jiang, the founder and CSO of Oxford Vacmedix, was invited to Buckingham Palace in London for the Royal Garden Party, an annual event that invites a broad range of people – all of whom have made a positive impact in their community – to be re...
Read More
Company News November 4, 2021 Oxford Vacmedix Comments: 0

First patient treated with novel Cancer Vaccine

A Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has started – the first clinical trial of a cancer vaccine using the novel technology. Press Release – Oxford group announces first patient treated with novel cancer vaccine Oxford, 4th November 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the start of a Phase 1 trial of OVM-200 with the first patient being treated at the prestigious Sarah...
Read More
Company News August 10, 2021 Oxford Vacmedix Comments: 0

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products Regulatory Authority). Ethics approval for the trial has al...
Read More
Company News
June 14, 2021 Oxford Vacmedix Comments: 0

Mark Thomas appointed as Head of Clinical Operations

Oxford Vacmedix UK Ltd announces the appointment of Mark Thomas as Head of Clinical Operations, bringing in-depth expertise in running clinical trials and in pharmaceutical development to Oxford Vacmedix. Press Release – appointment of Mark Thomas as Head of Clinical Operations Oxford, 14th June 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mark Thomas as the Head of Clinical Operations. He was previou...
Read More
Company News March 23, 2021 Oxford Vacmedix Comments: 0

Dr Thomas Morris appointed as Chief Medical Officer

Oxford Vacmedix UK Ltd announces the appointment of Dr Thomas Morris as Chief Medical Officer, bringing in-depth expertise in oncology clinical development to the Company. Press Release – Dr Thomas Morris appointed as Chief Medical Officer Oxford, 23rd March 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Dr. Thomas Morris BSc, MB BCh, LlM, MRCP FFPM as Chief Medical Officer.  Tom originally worked as a...
Read More
Company News January 4, 2021 Oxford Vacmedix Comments: 0

Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines

Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Oxford, UK – 4th January 2020 – FOR IMMEDIATE RELEASE Press Release – OVM CHAIN Collaboration Oxford 4th Jan 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that Heads of Terms for a Collaboration Agreement have been s...
Read More
Company News November 24, 2020 Oxford Vacmedix Comments: 0

Oxford Vacmedix announces filing of new patent for Covid-19 vaccine and diagnostics

New patent using Recombinant Overlapping Peptide (ROP technology) as novel approach to SARS-Cov-2 pandemic filed, after rapid development and initial testing Oxford, UK – 24th November 2020 – FOR IMMEDIATE RELEASE Press Release-Patent filed for Covid-19 vaccine and diagnostics 24-11-20 Oxford 24th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that research work on Covid-19 started earli...
Read More
en_GBEnglish
en_GBEnglish